Educational content on VJNeurology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The 41st Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) took place between September 24-26, 2025, in Barcelona, Spain. This meeting is the leading forum for advancing collaboration on groundbreaking research and innovative treatment strategies for people living with multiple sclerosis (MS) and related conditions.

ECTRIMS 2025

The 41st Congress of the European Committee for Treatment and Research in Multiple Sclerosis
24–26 September 2025 | Barcelona, Spain

ECTRIMS 2025

The 41st Congress of the European Committee for Treatment and Research in Multiple Sclerosis
24–26 September 2025 | Barcelona, Spain
The 41st Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) took place between September 24-26, 2025, in Barcelona, Spain. This meeting is the leading forum for advancing collaboration on groundbreaking research and innovative treatment strategies for people living with multiple sclerosis (MS) and related conditions.
Menopause and MS: overlapping symptoms and advice for management 3:03
Menopause and MS: overlapping symptoms and advice for management
Celia Oreja-Guevara • 20 Oct 2025
The clinical relevance of PRLs and SELs as MRI biomarkers in MS 4:32
The clinical relevance of PRLs and SELs as MRI biomarkers in MS
Alessandro Cagol • 16 Oct 2025
The relationship between serum biomarkers and spinal cord atrophy in MS 2:57
The relationship between serum biomarkers and spinal cord atrophy in MS
Alessandro Cagol • 16 Oct 2025
The effect of DMTs on brain volume loss and disability accumulation in MS 2:59
The effect of DMTs on brain volume loss and disability accumulation in MS
Alessandro Cagol • 16 Oct 2025
The use of the 2024 McDonald criteria for the diagnosis of prodromal MS 7:49
The use of the 2024 McDonald criteria for the diagnosis of prodromal MS
Serena Borrelli • 15 Oct 2025
Highlights from ECTRIMS 2025: updated diagnostic criteria, novel therapies, & more 2:29
Highlights from ECTRIMS 2025: updated diagnostic criteria, novel therapies, & more
Celia Oreja-Guevara • 20 Oct 2025
The impact of iron metabolism on MS disease activity and progression 1:57
The impact of iron metabolism on MS disease activity and progression
Alessandro Cagol • 16 Oct 2025
Addressing structural determinants of health in MS: improving patient care and outcomes 2:23
Addressing structural determinants of health in MS: improving patient care and outcomes
Mitzi Joi Williams • 6 Oct 2025
Assessing treatment efficacy in MS and NMOSD: moving beyond relapse rates 3:00
Assessing treatment efficacy in MS and NMOSD: moving beyond relapse rates
Celia Oreja-Guevara • 20 Oct 2025
The safety and efficacy of additional cycles of cladribine in MS: insights from a real-world study 2:14
The safety and efficacy of additional cycles of cladribine in MS: insights from a real-world study
Celia Oreja-Guevara • 20 Oct 2025
Further findings from a Phase I trial of CAR-T in MS: patient-reported outcomes 9:57
Further findings from a Phase I trial of CAR-T in MS: patient-reported outcomes
Jeffrey Dunn • 7 Oct 2025
The expansion of CAR T-cells into the bloodstream of patients with MS: insights from a Phase I trial 2:55
The expansion of CAR T-cells into the bloodstream of patients with MS: insights from a Phase I trial
Jeffrey Dunn • 7 Oct 2025
CAR-T therapy in MS: mechanism of action and potential adverse events 4:35
CAR-T therapy in MS: mechanism of action and potential adverse events
Jeffrey Dunn • 7 Oct 2025
The safety and feasibility of CAR-T in MS: findings from a Phase I trial 4:42
The safety and feasibility of CAR-T in MS: findings from a Phase I trial
Jeffrey Dunn • 7 Oct 2025
The use of bendamustine for lymphodepletion prior to CAR-T in MS: insights from a Phase I study 3:06
The use of bendamustine for lymphodepletion prior to CAR-T in MS: insights from a Phase I study
Jeffrey Dunn • 7 Oct 2025
The association of plasma neurofilament light chain, neuroaxonal loss, and patient-reported outcomes 2:15
The association of plasma neurofilament light chain, neuroaxonal loss, and patient-reported outcomes
Marcello Moccia • 2 Oct 2025
The content of VJNeurology is intended for healthcare professionals